+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Personalized Nanotechnology for Cell & Gene Therapies Market by Therapy Type (Cell Therapy, Gene Therapy), Nanotechnology Type (Nanocarrier Design, Nanodevices, Nanoencapsulation), Application, End User - Global Forecast 2025-2030- Product Image
Personalized Nanotechnology for Cell & Gene Therapies Market by Therapy Type (Cell Therapy, Gene Therapy), Nanotechnology Type (Nanocarrier Design, Nanodevices, Nanoencapsulation), Application, End User - Global Forecast 2025-2030- Product Image
Sale

Personalized Nanotechnology for Cell & Gene Therapies Market by Therapy Type (Cell Therapy, Gene Therapy), Nanotechnology Type (Nanocarrier Design, Nanodevices, Nanoencapsulation), Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 6055636
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Personalized Nanotechnology for Cell & Gene Therapies Market grew from USD 855.08 million in 2024 to USD 1.00 billion in 2025. It is expected to continue growing at a CAGR of 19.29%, reaching USD 2.46 billion by 2030.

The convergence of nanotechnology with cell and gene therapies has heralded a new era in personalized medicine. This dynamic field has evolved rapidly, driven by innovations that enable more effective targeting, delivery, and treatment of complex diseases. Advances in nanotechnology not only facilitate improved precision in therapeutic delivery but also open pathways for enhanced safety and efficacy, thereby transforming the way treatments are conceived and administered. The integration of tiny, engineered particles with biological systems offers unique advantages by reducing systemic toxicity while enhancing the concentration of therapeutic agents directly at the affected site. With the intertwining of rigorous scientific breakthroughs and clinical validation, stakeholders are now positioned to explore novel treatment modalities that were once considered out of reach.

In this evolving landscape, clinical and research communities are increasingly recognizing the role of personalized nanotechnology in tailoring interventions to individual patient profiles. Connectivity between multi-disciplinary research teams has reinforced the potential for nanotechnology to address cellular heterogeneity and genetic anomalies. As a result, significant investments in research and development are being channeled into technologies that promise to reshape the therapeutic paradigm. This report offers an in-depth analysis of these emerging trends and provides key insights into the market dynamics that continue to drive innovation in cell and gene therapies.

Transformative Shifts Reshaping the Personalized Nanotechnology Landscape

Recent years have witnessed transformative shifts that are redefining the integration of nanotechnology with cell and gene therapies. Advancements in nanomaterials and delivery systems have led to the development of more refined and adaptable treatment platforms. These innovations have allowed for meticulous control over the size, composition, and functionalization of nanoparticles, providing the versatility needed for tailored therapeutic applications. The emergence of smart nanocarriers with responsive properties further underscores the significance of these breakthroughs, as they enable controlled release in response to specific physiological triggers.

The landscape is also experiencing a paradigm shift with increasing acceptance of combined therapeutic strategies that incorporate both cell-based interventions and gene editing technologies. This synergy is fostering more robust treatment options for conditions that were previously very challenging to manage. Moreover, ongoing research is unraveling new methods to overcome traditional barriers such as immune clearance and off-target effects, thereby enhancing patient outcomes. The sector’s momentum is driven by collaborative efforts between academia, clinical practitioners, and industry leaders, all of whom are leveraging the convergence of nanotechnology, cell therapy, and gene therapy to unlock unprecedented clinical benefits. This evolution not only indicates a shift in treatment methodologies but also signals broader implications for regulatory frameworks and market adoption rates.

Key Segmentation Insights in Cell & Gene Therapy Applications

A detailed evaluation of market segments reveals insightful trends that underscore the diverse landscape of personalized nanotechnology in cell and gene therapies. When analyzed based on therapy type, the market dissects into two primary domains: Cell Therapy and Gene Therapy. Within Cell Therapy, sub-segments such as Immune Cell Therapy, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, and Stem Cell Therapy each play vital roles in defining therapeutic potentials, reflecting ongoing research and specialized clinical applications. Meanwhile, Gene Therapy is parsed into distinct yet interrelated facets, including CRISPR Technology, innovative Delivery Mechanisms, complex Gene Modification Methods, and the adoption of Non-Viral Vectors. These intricate subdivisions reveal the layered complexity of treatments available and expose the potential for more targeted, patient-specific interventions.

Another important perspective comes from the analysis of nanotechnology types. The capabilities of the industry are broadened through a focus on nanocarrier design and the use of sophisticated nanodevices, coupled with techniques like nanoencapsulation, which improves drug stability and pharmacokinetics. In addition, the integration of nanomaterials and developments in nanomedicine have accentuated the precision of therapeutic interventions, while nanostructure imaging offers improved diagnostic and monitoring tools. Further segmentation by application illustrates the strategic targeting of key therapeutic areas such as cancer therapies, cardiovascular diseases, inherited genetic disorders, and neurological disorders. Moreover, the market is critically influenced by the end user dimension, which encompasses a diverse array of stakeholders including diagnostic centers, healthcare facilities, pharmaceutical companies, and research institutions. This multi-layered segmentation not only provides clarity on current market demand but also helps in forecasting emerging trends in therapy reimbursement and policy development.

Based on Therapy Type, market is studied across Cell Therapy and Gene Therapy. The Cell Therapy is further studied across Immune Cell Therapy, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, and Stem Cell Therapy. The Gene Therapy is further studied across CRISPR Technology, Delivery Mechanisms, Gene Modification Methods, and Non-Viral Vectors.

Based on Nanotechnology Type, market is studied across Nanocarrier Design, Nanodevices, Nanoencapsulation, Nanomaterials, Nanomedicine, and Nanostructure Imaging.

Based on Application, market is studied across Cancer Therapies, Cardiovascular Diseases, Inherited Genetic Disorders, and Neurological Disorders.

Based on End User, market is studied across Diagnostic Centers, Healthcare Facilities, Pharmaceutical Companies, and Research Institutions.

Regional Dynamics Influencing Market Evolution

Regional analysis adds another facet to understanding the development of personalized nanotechnology for cell and gene therapies. In North America, particularly within the Americas, robust research infrastructure and substantial funding combined with a favorable regulatory environment have encouraged rapid innovation. In parallel, regions across Europe, the Middle East, and Africa are carving out significant niches characterized by strategic partnerships and joint ventures that leverage local expertise and comprehensive healthcare networks. The fusion of academic excellence and industrial prowess in these regions is steadily transforming market dynamics, thereby facilitating accelerated product development and broader clinical adoption.

Conversely, the Asia-Pacific region, with its vast and diverse population base, supports a vibrant ecosystem of biotech startups, academic institutions, and government initiatives. This has resulted in the expansion of cutting-edge research, particularly in integrating nanotechnology with advanced cell and gene therapies. An emerging trend is the increasing cross-border collaborations that amplify research capabilities and streamline regulatory pathways, further enhancing the market’s global footprint. Therefore, understanding these regional nuances is critical for businesses looking to navigate complex regulatory environments and harness localized opportunities for sustainable growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Pioneering Companies Driving Innovation in Nanotechnology

The competitive landscape in personalized nanotechnology for cell and gene therapies is marked by the presence of trailblazing companies that are pushing the boundaries of innovation. Industry giants such as AbbVie Inc. and Amgen Inc. have demonstrated substantial investments in the development and commercialization of novel therapeutics. Organizations like Arcturus Therapeutics, Inc. and AstraZeneca PLC continue to leverage cutting-edge research to enhance the precision and reliability of treatment modalities, while BASF Pharma Solutions and BlueWillow Biologics Inc. consistently contribute to new material developments pivotal for nanoparticle design.

Leading pharmaceutical companies including Bristol-Myers Squibb Company, Celgene, Inc., and Novartis AG are at the forefront of integrating nanotechnology with sophisticated gene modification techniques to address unmet therapeutic needs. Other influential players such as Camurus AB, Cristal Therapeutics, and Cytimmune Sciences have made significant strides in refining both nanocarrier systems and delivery mechanisms. Esteemed laboratories and commercial organizations, including Eisai Co., Ltd., EyePoint Pharmaceuticals, and Gilead Sciences Inc., continue to support clinical validation processes that underpin market expansion. Further, companies like GlaxoSmithKline PLC and Hoffmann-La Roche Ltd. are recognized for their targeted research and data-driven strategies that align with the demands of modern therapies. This mosaic is rounded out by highly reputed entities such as Ipsen Pharma, Johnson & Johnson, Merck KGaA, Nanobiotix SA, Pfizer Inc., Spark Therapeutics, Inc., Teva Pharmaceutical Industries Limited, and Thermo Fisher Scientific Inc. Their concerted focus on innovation, strategic partnerships, and process optimization not only drives industry momentum but also ensures that advancements in personalized nanotechnology are rapidly translated from bench to bedside.

The report delves into recent significant developments in the Personalized Nanotechnology for Cell & Gene Therapies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Arcturus Therapeutics, Inc., AstraZeneca PLC, BASF Pharma Solutions, BlueWillow Biologics Inc., Bristol-Myers Squibb Company, Camurus AB, Celgene, Inc., Cristal Therapeutics, Cytimmune Sciences, Eisai Co., Ltd., EyePoint Pharmaceuticals, Gilead Sciences Inc., GlaxoSmithKline PLC, Hoffmann-La Roche Ltd, Ipsen Pharma, Johnson & Johnson, Merck KGaA, Nanobiotix SA, Novartis AG, Pfizer Inc., Spark Therapeutics, Inc., Teva Pharmaceutical Industries Limited, and Thermo Fisher Scientific Inc..

Actionable Recommendations for Industry Leaders

Industry leaders looking to capitalize on the rapid advancements in personalized nanotechnology for cell and gene therapies should consider several strategic recommendations. Foremost, there is a critical need to integrate cross-disciplinary expertise. By bridging the gap between advanced nanotechnology, molecular biology, and clinical practice, companies can accelerate the translation of promising technologies into viable therapeutic solutions. Leaders are encouraged to foster collaborative ecosystems that bring together academic institutions, biotech startups, and regulatory bodies in order to streamline the innovation pipeline.

Investments in digital infrastructure that support big data analytics and real-time monitoring are essential to manage quality control and optimize personalized treatments. Furthermore, adopting a proactive approach to regulatory compliance will allow organizations to navigate the complex international marketplace with greater agility. Research and development initiatives should maintain a focus on modular and scalable solutions that can be rapidly adapted to emerging clinical insights. Strategic portfolio diversification that balances high-risk, high-reward projects alongside more conventional approaches can help mitigate market unpredictability. Finally, nurturing an environment of continuous learning and iterative improvement is vital. Emphasizing feedback loops from clinical trials, post-market surveillance, and patient outcomes will ensure that businesses remain ahead of the curve in an increasingly competitive field.

Strategic Perspectives on the Future

The evolving landscape of personalized nanotechnology for cell and gene therapies is a testament to the profound impact of interdisciplinary innovation on modern medicine. This report illustrates how targeted advancements in nanotechnology have not only enhanced the precision of therapeutic interventions but have also enabled more personalized, effective treatment strategies. The interplay between sophisticated nanocarrier systems and advanced cell and gene therapies is driving a paradigm shift that promises to redefine patient care and clinical outcomes.

Stakeholders are now presented with unprecedented opportunities to transform therapeutic modalities, as research and commercial initiatives converge to meet complex clinical needs. The detailed segmentation insights, regional dynamics, and competitive analysis offered in this report provide a robust framework to understand both current trends and future market potential. Overall, the strategic perspectives outlined underscore the importance of collaboration, innovation, and forward-thinking investments in shaping a future where personalized medicine becomes the cornerstone of healthcare.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of chronic diseases globally
5.1.1.2. Increasing adoption of precision medicine worldwide
5.1.1.3. Government and regulatory support amplifying research and innovations in nanotechnology applications
5.1.2. Restraints
5.1.2.1. High research and development costs associated with nanotechnology in cell and gene therapies
5.1.3. Opportunities
5.1.3.1. Ongoing innovations in leveraging nanotechnology in orally administered gene therapies
5.1.3.2. Development of targeted nano-delivery systems
5.1.4. Challenges
5.1.4.1. Navigating regulatory complexities in personalized nanotechnology for cell and gene therapies
5.2. Market Segmentation Analysis
5.2.1. Therapy Type: Proliferating need for immune cell therapy for personalized treatments
5.2.2. Application: Rising significance of nanotechnology in cancer therapies
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Personalized Nanotechnology for Cell & Gene Therapies Market, by Therapy Type
6.1. Introduction
6.2. Cell Therapy
6.2.1. Immune Cell Therapy
6.2.2. Induced Pluripotent Stem Cells
6.2.3. Mesenchymal Stem Cells
6.2.4. Stem Cell Therapy
6.3. Gene Therapy
6.3.1. CRISPR Technology
6.3.2. Delivery Mechanisms
6.3.3. Gene Modification Methods
6.3.4. Non-Viral Vectors
7. Personalized Nanotechnology for Cell & Gene Therapies Market, by Nanotechnology Type
7.1. Introduction
7.2. Nanocarrier Design
7.3. Nanodevices
7.4. Nanoencapsulation
7.5. Nanomaterials
7.6. Nanomedicine
7.7. Nanostructure Imaging
8. Personalized Nanotechnology for Cell & Gene Therapies Market, by Application
8.1. Introduction
8.2. Cancer Therapies
8.3. Cardiovascular Diseases
8.4. Inherited Genetic Disorders
8.5. Neurological Disorders
9. Personalized Nanotechnology for Cell & Gene Therapies Market, by End User
9.1. Introduction
9.2. Diagnostic Centers
9.3. Healthcare Facilities
9.4. Pharmaceutical Companies
9.5. Research Institutions
10. Americas Personalized Nanotechnology for Cell & Gene Therapies Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Personalized Nanotechnology for Cell & Gene Therapies Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Personalized Nanotechnology for Cell & Gene Therapies Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2024
13.2. FPNV Positioning Matrix, 2024
13.3. Competitive Scenario Analysis
13.3.1. Poseida Therapeutics agreed to be acquired by Roche Holdings
13.3.2. Envoya's nanoparticle technology significantly enhances nucleic acid encapsulation
13.3.3. Cellevate to re-launch its innovative Cellevat3d nanofiber microcarriers
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET MULTI-CURRENCY
FIGURE 2. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET MULTI-LANGUAGE
FIGURE 3. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET RESEARCH PROCESS
FIGURE 4. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2024 VS 2030 (%)
FIGURE 11. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 13. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 15. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 17. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 19. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 25. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET DYNAMICS
TABLE 7. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY IMMUNE CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CRISPR TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY DELIVERY MECHANISMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE MODIFICATION METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOCARRIER DESIGN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANODEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOENCAPSULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOMATERIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOMEDICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOSTRUCTURE IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CANCER THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY INHERITED GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 58. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 59. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 60. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 64. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 65. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 89. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 90. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 91. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 92. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 95. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 96. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 97. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 98. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 107. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 108. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 109. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 110. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 116. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 122. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 127. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 128. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 133. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 134. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 139. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 140. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 143. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 144. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 145. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 146. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 151. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 152. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 161. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 162. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 163. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 164. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 165. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 168. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 169. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 170. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 171. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 175. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 176. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 177. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 180. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 181. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 182. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 183. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 186. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 187. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 188. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 189. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 194. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 195. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 198. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 199. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 200. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 201. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 217. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 218. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 219. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 222. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 223. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 224. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 225. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 228. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 229. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 230. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 231. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. SPAIN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 252. SPAIN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
TABLE 253. SPAIN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
TABLE 254. SPAIN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
TABLE 255. SPAIN PERSONALIZED NANOTECHNOLOGY FO

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Arcturus Therapeutics, Inc.
  • AstraZeneca PLC
  • BASF Pharma Solutions
  • BlueWillow Biologics Inc.
  • Bristol-Myers Squibb Company
  • Camurus AB
  • Celgene, Inc.
  • Cristal Therapeutics
  • Cytimmune Sciences
  • Eisai Co., Ltd.
  • EyePoint Pharmaceuticals
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Hoffmann-La Roche Ltd
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck KGaA
  • Nanobiotix SA
  • Novartis AG
  • Pfizer Inc.
  • Spark Therapeutics, Inc.
  • Teva Pharmaceutical Industries Limited
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.46 Billion
Compound Annual Growth Rate19.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Cell & Gene Therapy Drug Delivery Devices Market by Products, Commercialized Drugs - Global Forecast 2025-2030 - Product Image

Cell & Gene Therapy Drug Delivery Devices Market by Products, Commercialized Drugs - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Nanomedicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Nanomedicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Personalized Medicine Market - Types, Technologies and Applications - Product Image

Personalized Medicine Market - Types, Technologies and Applications

  • Report
  • 341 Pages
  • Global
From
Gene Delivery Technologies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Gene Delivery Technologies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 181 Pages
  • Global
From
Gene Delivery Technologies Market Report 2025 - Product Image

Gene Delivery Technologies Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.